MPS Q1 FY27: A record quarter, and a clearer operating model

MPS opened FY27 with its strongest first quarter on record. Consolidated revenue in Q1 FY27 rose 20.38% year on year to INR 224.24 crores. EBITDA grew much faster, up 53.03% to INR 76.96 crores, taking EBITDA margin to 34.32% from 27.00% in Q1 FY26. PAT increased 42.99% to INR 50.39 crores, and basic EPS was INR 29.70, an all-time Q1 high.

The quarter mattered not only because revenue grew, but because growth converted sharply into profits. Headcount increased just 2.73% year on year to 3,352, while EBITDA expanded materially. Management framed this as the company’s operating leverage showing up cleanly in the numbers.

The quarter in numbers, and what changed underneath

MPS described the period as a “Rule of 50” quarter, with revenue growth of about 20% and EBITDA margin of about 34% together clearing 50. The company also highlighted that excluding AJE, which it said is “resetting by design”, underlying momentum was stronger.

Excluding AJE, reported revenue was INR 198.47 crores in Q1 FY27, up 28.38% year on year. EBITDA excluding AJE was INR 66.95 crores, up 56.53%, with EBITDA margin at 33.73%.

The balance sheet commentary was straightforward. Cash and cash equivalents stood at INR 138.02 crores as of 30 June 2026, while borrowings were INR 37.63 crores, linked to the Unbound Medicine acquisition. Working capital remained stable with DSO at 45 days, improving from 51 days at the end of Q4 FY26.

Segment performance: Research steady, Education accelerates, Corporate Learning turns

MPS has three operating segments: Research Solutions, Education Solutions, and Corporate Learning. The quarter showed a continued shift in revenue mix toward Education.

Research Solutions remained the anchor, contributing 55.0% of Q1 FY27 revenue. Segment revenue rose 13.22% year on year to INR 123.23 crores. More important for the operating model was margin expansion. Research EBITDA increased 37.88% to INR 55.54 crores and EBITDA margin widened to 45.07%.

Management repeatedly linked Research profitability to AI-enabled delivery moving from pilots into production. DigiCore, described as the company’s AI-enabled production ecosystem, is now live in client delivery. Research Integrity Check was positioned as an added control layer to detect paper mills, identity fraud, and image manipulation. The broader argument was that the bottleneck in research is shifting from content generation toward verification and integrity, and that MPS is aligning its services and tooling to that part of the workflow.

Education Solutions was the fastest growing segment. Revenue rose 42.21% year on year to INR 73.41 crores, while EBITDA grew 39.14% to INR 25.74 crores. EBITDA margin for the segment was 35.06%.

A key driver was Unbound Medicine, which delivered its first full quarter inside MPS. Management described Unbound as a recurring, high-renewal subscription business anchored in medicine and nursing. Operationally, one visible impact was in the client count. The company billed 841 clients in Q1 FY27 versus 404 in Q1 FY26, attributed to Unbound’s institutional subscriber base being added to MPS’ portfolio.

Corporate Learning showed the clearest signs of a turnaround from the prior year’s stress. Revenue increased 6.89% to INR 27.60 crores, while EBITDA rose 60.69% to INR 6.99 crores. EBITDA margin expanded to 25.33% from 16.85% a year ago. Headcount declined 33.17% year on year to 135, reflecting restructuring and a deliberate shift toward a leaner delivery model.

Strategy themes: outcomes-based revenue, AI in production, and disciplined integration

Across the investor presentation and the call, management returned to two connected themes.

First, it said revenue is shifting from being paid for effort to being paid for outcomes. Examples mentioned included manuscript acceptance outcomes in author solutions, paper-mill detection as a trusted integrity decision for publishers, accessible learning assets delivered at scale, recurring renewals in Unbound, and performance-focused enterprise capability programs in Corporate Learning.

Second, MPS emphasised that AI is already embedded in delivery and not positioned as a slideware story. In Research, AI-enabled composition and quality workflows were described as live in customer delivery, supporting “one-touch” workflows and AI-driven quality checks. In Education, the company referenced a growing line where clients pay MPS to review and quality-check AI-generated instructional content. In Corporate Learning, management highlighted BridgeAI and broader AI enablement across learning assets, translations, evaluation rubrics, and quality assurance.

Unbound Medicine was discussed as a strategic acquisition because it adds a predictable subscription model and a long tail of institutional accounts. Management said it is integrating deliberately and is learning the renewal cycle before committing to synergy timelines. On the call, it shared that Unbound’s monthly run rate is about USD 800,000 and current margins are in the range of 18% to 20%, with an expectation to improve from there.

Guidance and what the market will track next

Management reiterated FY27 guidance to comfortably cross INR 300 crores in EBITDA. It stressed that this is built bottom-up from segment operating plans and should be read as a floor rather than a ceiling. It also noted that Q1 EBITDA of INR 76.96 crores is about 26% of the full-year mark, and that the company’s second half has historically outperformed the first.

In response to an investor question, management also restated previously discussed FY28 targets of approximately INR 1,500 crores in revenue and around INR 450 crores in EBITDA.

On acquisitions, leadership indicated an active pipeline, with a preference for targets above USD 15 million in revenue, and with Education as the key focus area. It also stated a financing preference for cash accruals plus debt, and that equity issuance is unlikely in the base case.

The key investor watchpoints remain visible from the quarter’s disclosures: customer concentration is still meaningful with the top five clients contributing 46% of revenue, and AJE continues to be described as a business in reset mode. At the same time, the quarter demonstrated that MPS is capable of expanding margins while growing, and that Education is becoming a larger pillar without weakening the Research base.

If FY26 was positioned as the year the operating system was proven, management is framing FY27 as the year it compounds. Q1 FY27 gave tangible evidence of that compounding through record revenue, step-up profitability, and reiterated guidance.